secwatch.observer — SEC 8-K summary
======================================

Issuer:     IDEAYA Biosciences, Inc. (IDYA)
CIK:        0001676725
Form:       8-K
Filed at:   2025-12-05T23:59:59+00:00
Accession:  0001193125-25-309716
Event type: other_material
Sentiment:  negative
Materiality: 0.65
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud@v2

GSK terminates collaboration; IDEAYA regains IDE275 and IDE705; cash runway unchanged
--------------------------------------------------------------------------------

- GSK terminates Collaboration, Option and License Agreement effective 90 days after Dec 4, 2025; programs transferred back to IDEAYA.
- IDEAYA to evaluate strategic options for IDE275 (Werner Helicase) and IDE705 (Pol Theta) in 2026.
- Company reaffirms cash runway into 2030, unchanged by the termination.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1676725/000119312525309716/0001193125-25-309716-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1676725/000119312525309716/d87387d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-309716

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer